Design and synthesis of pyridazinone-based 5-HT2C agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 19, 2009, Pages 5791-5795

  Allerton, Charlotte M N ^a   Andrews, Mark D ^a   Blagg, Julian ^a   Ellis, David ^a   Evrard, Edel ^a   Green, Martin P ^a   Liu, Kevin K C ^b   McMurray, Gordon ^a   Ralph, Michael ^a   Sanderson, Vivienne ^a   Ward, Robin ^a   Watson, Lesa ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

5 HT2C; Agonist; CNS penetration; Pyridazinone

Indexed keywords

PYRIDAZINONE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VIVO STUDY; NONHUMAN; STRESS INCONTINENCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOGS; DRUG DESIGN; HUMANS; PIPERAZINES; PYRIDAZINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY INCONTINENCE, STRESS;

EID: 69949109731     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.136     Document Type: Article

References (25)

1. Hoyer D., Clarke D.E., and Fozard J.R. Pharmacol. Rev. 46 (1994) 157
2. Saxena P.R. Pharmacol. Rev. 66 (1994) 339
3. Bishop M.J., and Nilsson B.M. Exp. Opin. Ther. Pat. 13 (2003) 1691
4. Ramage A.G. Br. J. Pharmacol. 147 (2006) S120
5. Millard R.J., Moore K., Rencken R., Yalcin I., and Bump R.C. BJU Int. 93 (2004) 311
6. Thor K.B. Urology 62 (2003) 3
7. Conlon, K.; Miner, W.; Christy, C.; McCleary, S.; Brinkman, H.; Rees, H.; McMurray, G. Program No. 48.14. 2005, Neuroscience Abstract Viewer. Washington, DC: Society for Neuroscience, 2005.
8. McMurray G., and Miner W. FASEB J. 19 (2005) A536
9. Kimura Y., Naitou Y., Wanibuchi F., and Yamaguchi T. J. Urol. 175 (2006) 1953
10. Nedergaard P., Sannchez C., and Mellerup E. Behav. Brain Res. 149 (2004) 151
11. Leysen J.E. Curr. Drug Targets: CNS Neurol. Disord. 3 (2004) 11
12. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., and Roth B.L. Circulation 102 (2000) 2836
13. Fiorella D., Rabin R.A., and Winter J.C. Psychopharmacology 119 (1995) 222
14. McCann J., and Ames B.N. Proc. Natl. Acad. Sci. U.S.A. 271 (1976) 5
15. McCann J., Choi E., Yamasaki E., and Ames B.N. Proc. Natl. Acad. Sci. 72 (1975) 5135
16. Maron D.M., and Ames B.N. Mutat. Res. 113 (1983) 173
17. 2C receptor. Andrews, M.; Blagg, J.; Brennan, P.; Fish, P. V.; Roberts, L.; Storer, R. I.; Whitlock, G. A. WO patent 117169, 2008.
18. 2C receptor utilizing SPA technology and cellular membrane preparations generated from recombinant Swiss 3T3 cells. Andrews, M.; Blagg, J.; Brennan, P.; Fish, P. V.; Roberts, L.; Storer, R. I.; Whitlock, G. A. WO patent 117169, 2008.
19. 2B receptor.
20. Vanags D.M., Rodgers S.E., Duncan E.M., Lloyd J.V., and Bochner F. Br. J. Pharmacol. 106 (1992) 917
21. Borman R.A., Tilford N.S., Harmer D.W., Day N., Ellis E.S., Sheldrick R.L., Carey J., Coleman R.A., and Baxter G.S. Br. J. Pharmacol. 135 (2002) 1144
22. O'Neill A.B., Buckner S.A., Brune M.E., Milicic I., Daza A.V., Gauvin D.M., Altenbach R.J., Meyer M.D., Williams M., Sullivan J.P., and Brioni J.G. Life Sci. 70 70 (2001) 181
23. Conlon, K.; Christy, C.; Westbrook, S.; Whitlock, G.; Roberts, L.; Stobie, A.; McMurray, G. J. Pharmacol. Exp. Ther. 2009, in press. doi:10.1124/jpet.109.154963v1 .
24. The dichloropyridazine required for the synthesis of 4 was synthesised according to:. Horning R.H., and Amstutz E.D. J. Org. Chem. 20 (1955) 707
25. Kuraishi T. Pharm. Bull. 5 (1957) 587